(50)The Commission should establish a so-called Consultation Forum. The Consultation Forum should ensure the balanced participation of Member States’ representatives and representatives of relevant stakeholders, including environmental organisations, representatives of healthcare and patient association as well as representatives of manufacturers, operators and certified persons. The Consultation Forum should, where relevant, involve the European Medicines Agency.